Vertex Pharmaceuticals Incorporated (VRTX) Financial Statements (2026 and earlier)

Company Profile

Business Address 50 NORTHERN AVENUE
BOSTON, MA 02210
State of Incorp. MA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,15311,26410,8957,7566,8553,808
Cash and cash equivalent4,57010,36910,5046,7955,9883,109
Short-term investments1,583895391961866699
Restricted cash and investments      8
Receivables1,6091,5631,4421,137885634
Inventory, net of allowances, customer advances and progress billings1,205739461353281168
Inventory1,205739461353281168
Prepaid expense 102109112   
Other current assets 768474187  
Other undisclosed current assets451385251128113206
Total current assets:9,59614,14413,2359,5618,1334,823
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization 58273316400431445
Operating lease, right-of-use asset1,35729434733032688
Property, plant and equipment 635940   
Long-term investments and receivables5,1082,498    
Long-term investments5,1082,498    
Intangible assets, net (including goodwill)1,9141,9281,6921,4021,4021,402
Goodwill1,0881,0881,0881,0021,0021,002
Intangible assets, net (excluding goodwill)826840604400400400
Restricted cash and investments      3
Deferred income tax assets2,3311,8121,2479358831,191
Other noncurrent assets99989552211149158
Other undisclosed noncurrent assets1,107828753694527208
Total noncurrent assets:12,9378,5864,9163,8723,6183,496
TOTAL ASSETS:22,53322,73018,15113,43311,7528,318
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,2023,0202,4311,8741,5601,205
Accounts payable41336530419515588
Accrued liabilities2,7892,6552,1271,6791,4051,117
Other liabilities363527312268317130
Total current liabilities:3,5653,5472,7422,1421,8781,335
Noncurrent Liabilities
Long-term debt and lease obligation 113376431887890539
Finance lease, liability 113376431510539539
Liabilities, other than long-term debt2,4461,2261,065303298360
Other liabilities902878686117108183
Operating lease, liability1,544349380377350 
Business combination, contingent consideration, liability    187190177
Total noncurrent liabilities:2,5591,6021,4961,1911,187898
Total liabilities:6,1245,1504,2383,3333,0652,233
Equity
Equity, attributable to parent16,41017,58013,91310,1008,6876,085
Common stock333333
Additional paid in capital6,6727,4507,3876,8817,8947,938
Accumulated other comprehensive income (loss)128(14)116(68)(2)
Retained earnings (accumulated deficit)9,60710,1426,5233,201859(1,853)
Total equity:16,41017,58013,91310,1008,6876,085
TOTAL LIABILITIES AND EQUITY:22,53322,73018,15113,43311,7528,318

Income Statement (P&L) ($ in millions)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues11,0209,8698,9317,5746,2064,163
Cost of revenue(1,531)(1,262)(1,080)(904)(749)(552)
Cost of product and service sold(1,531)(1,262)(1,080)(904)(736)(548)
Gross profit:9,4908,6077,8506,6705,4563,611
Operating expenses(9,723)(4,827)(3,601)(3,891)(2,600)(2,413)
Other undisclosed operating income152583  
Operating income (loss):(233)3,8324,3072,7822,8561,198
Nonoperating income (expense)512592(20)10319256
Investment income, nonoperating59861514552264
Other nonoperating income (expense)(86)(23)(165)5296192
Interest and debt expense(31)(39)(44)(47)(58)(59)
Income from continuing operations before equity method investments, income taxes:2494,3854,2442,7453,1171,395
Other undisclosed loss from continuing operations before income taxes  (5)(11)(14)  
Income from continuing operations before income taxes:2494,3804,2322,7303,1171,395
Income tax expense(784)(760)(910)(388)(405)(218)
Income (loss) from continuing operations:(536)3,6203,3222,3422,7121,177
Income before gain (loss) on sale of properties:2,3422,7121,177
Net income (loss) available to common stockholders, diluted:(536)3,6203,3222,3422,7121,177

Comprehensive Income ($ in millions)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(536)3,6203,3222,3422,7121,177
Other comprehensive income (loss)(1)3  (67)(3)
Comprehensive income (loss):(536)3,6223,3222,3422,6451,174
Other undisclosed comprehensive income (loss), net of tax, attributable to parent143(18)(15)84  
Comprehensive income (loss), net of tax, attributable to parent:(394)3,6053,3072,4272,6451,174

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: